Therefore, our findings suggested that SLFN11 may act as a critical prognostic indicator to identify HCC patients with shorter OS and higher recurrence rates, and may provide new insight into novel therapies to improve the prognosis of HCC patients. Here, SLFN11 is linked to hepatocellular carcinoma.